| Phase 1 | 1 | |
| Phase 1/2 | 2 | |
| Phase 2 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC | Castration-resistant Prostate Cancer | Recruiting | 2026-04-23 |
| Phase 1/2 | ||||
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression | Uveal Melanoma | Recruiting | 2025-07-14 |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic… | Triple Negative Breast Cancer | Recruiting | 2025-05-15 |
| Phase 1 | ||||
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis | Uveal Melanoma, Metastatic | Recruiting | 2026-04-23 |
| Not applicable | ||||
| NCT07552922 | Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1 | Prostate Cancer (Adenocarcinoma) | Recruiting | 2026-04-27 |
Melanoma (2) · Prostate Cancer (2) · Breast Cancer (1) · Triple-Negative Breast Cancer (1)